The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2021 / Jan / The 2020 Cell and Gene Therapy Supplement
Business & Regulation Cell & Gene Business & Trends Supply Chain Sponsored

The 2020 Cell and Gene Therapy Supplement

The cell and gene therapy industry remains strong at the end of a difficult year – according to industry experts in The Medicine Maker 2020 Cell and Gene Therapy Supplement.

By James Strachan 01/07/2021 1 min read

Sponsored By

MilliporeSigma, Sartorius

Share

In my editorial for our last cell and gene therapy supplement, I wrote that many in the industry wouldn't be preoccupied with full stockings in the weeks leading up to Christmas, “but rather full schedules – with many conferences to attend.” Oh how times have changed!

This year’s supplement features Kelly Page, Head of Global Cell Therapy Commercialization at Takeda, Sandy Macrae, CEO of Sangamo Therapeutics, and David Meek, CEO of FerGene, who discuss what excites them the most about the field. We also get the cell and gene story from the ISCT – the society that was there at the very beginning – and interview Vered Caplan, CEO of Orgenesis.

You can find out more about the supplement and download the PDF here.

For weekly updates on the cell and gene therapy industry, subscribe to the Cell & Gene Curator newsletter

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

Recommended

Related Content

Do Pharma Supply Chains Have a Visibility Problem?
Supply Chain Business & Trends Future of Pharma
Do Pharma Supply Chains Have a Visibility Problem?

August 4, 2026

4 min read

A recent multimillion-dollar freezer failure highlights the urgent need for real-time visibility across the pharmaceutical supply chain

What the Iran War Means for Pharma Supply Chains
Supply Chain Business & Trends
What the Iran War Means for Pharma Supply Chains

June 29, 2026

7 min read

Argon & Co’s Michel Savini discusses the medicines most exposed to geopolitical instability, and why scenario planning remains underused across life sciences

Pharma Supply Chains in the Crossfire
Supply Chain Cell & Gene Business & Trends
Pharma Supply Chains in the Crossfire

May 5, 2026

6 min read

How tariff uncertainty and geopolitical tensions are reshaping pharmaceutical logistics

A Reliable Cold Chain is a Health Equity Issue
Biopharma Supply Chain Supply Chain
A Reliable Cold Chain is a Health Equity Issue

April 21, 2026

4 min read

Why temperature-controlled logistics is a critical but overlooked foundation of equitable access to medicines

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: